Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.

MLA

Fong, Peter C. C., et al. “Coformulation of Pembrolizumab and Vibostolimab in Patients (Pts) with Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (MCRPC): KEYNOTE-365 Cohort G.” Journal of Clinical Oncology, vol. 42, Feb. 2024, p. 149. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.4_suppl.149.

APA

Fong, P. C. C., Kwiatkowski, M., Mosca, A., Perez Valderrama, B., Huang, Y.-H., Zedan, A. H., Kuc, K., Wiechno, P., Laguerre, B., Gonzalez-Billalabeitia, E., Osipov, M., Sener Dede, D., Goh, J., Daugaard, G., Zhu, P., Imai, K., liu, yingjie, & Arranz Arija, J. A. (2024). Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G. Journal of Clinical Oncology, 42, 149. https://doi.org/10.1200/JCO.2024.42.4_suppl.149

Chicago

Fong, Peter C.C., Mariusz Kwiatkowski, Alessandra Mosca, Begona Perez Valderrama, Yi-Hsiu Huang, Ahmed H. Zedan, Kamil Kuc, et al. 2024. “Coformulation of Pembrolizumab and Vibostolimab in Patients (Pts) with Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (MCRPC): KEYNOTE-365 Cohort G.” Journal of Clinical Oncology 42 (February): 149. doi:10.1200/JCO.2024.42.4_suppl.149.